Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Rigel Pharmaceuticals, Inc. (RIGL), Synta Pharmaceuticals Corp. (SNTA): Three Horrendous Health-Care Stocks This Week

Page 1 of 2

Many stocks encountered turbulence this week, but few were blown about like several biotech stocks. Here are the three most horrendous performers in health care over the first week of June.

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)

Underwhelming

Synta Pharmaceuticals Corp. (NASDAQ:SNTA) announced results from a mid-stage clinical study this week for lung cancer drug ganetespib. Shares plunged 38% as investors reacted. Did the drug fail completely? Actually, no.

Patients taking a combination of ganetespib and the chemotherapy docetaxel lived a median of 9.8 months. Other patients taking only docetaxel lived a median of 7.4 months. That’s a 32% improvement. Even better improvement of 67% was experienced by patients whose cancer was diagnosed at least six months before the initiation of the study. Synta Pharmaceuticals Corp. (NASDAQ:SNTA)’s results sound really good, right?

There are a couple of problems, though. First, results from the study announced late last year indicated more dramatic improvement. Second, the difference in numbers of patient deaths between the two groups of patients is small. Investors appear to be losing confidence that ganetespib will live up to earlier expectations.

No win for the spin
Another biotech, Infinity Pharmaceuticals Inc. (NASDAQ:INFI), also announced clinical results this week. The company’s press release trumpeted “encouraging” findings for its experimental leukemia drug. Mr. Market didn’t appear to buy the spin. Infinity Pharmaceuticals Inc. (NASDAQ:INFI) shares tanked nearly 33% for the week.

The catalyst behind the sell-off stemmed from safety concerns about IPI-145, the drug tested in the phase 1 study. Some patients who took the treatment died, although Dr. Steven Horwitz of the Memorial Sloan-Kettering Cancer Center pointed out early in the week that these patients had undergone transplants and were very ill.

Another issue is fear over potential rivals. Gilead Sciences, Inc. (NASDAQ:GILD), for example, reported in May that its idelalisib produced significant tumor shrinkage in half of the patients involved in an early-stage trial. Dr. Sandra Swain, president of the American Society of Clinical Oncology, called the results “pretty incredible.” Gilead Sciences, Inc. (NASDAQ:GILD) is also testing idelalisib in the treatment of non-Hodgkin’s lymphoma.

Pain-medication pain

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) experienced pain this week, resulting from its drug intended to help rheumatoid arthritis patients suffer less pain. Shares fell almost 23%.
AstraZeneca plc (ADR) (NYSE:AZN), which has partnered with Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) on fostamatinib, opted to turn all rights for the drug back over to Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL). The British drugmaker decided not to pursue an approval path for the drug after disappointing clinical results. AstraZeneca plc (ADR) (NYSE:AZN) will take a $140 million hit in the second quarter from the move.
Page 1 of 2
Loading Comments...